Your browser doesn't support javascript.
loading
MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer.
Yoshida, Ryohei; Saigi, Maria; Tani, Tetsuo; Springer, Benjamin F; Shibata, Hirofumi; Kitajima, Shunsuke; Mahadevan, Navin R; Campisi, Marco; Kim, William; Kobayashi, Yoshihisa; Thai, Tran C; Haratani, Koji; Yamamoto, Yurie; Sundararaman, Shriram K; Knelson, Erik H; Vajdi, Amir; Canadas, Israel; Uppaluri, Ravindra; Paweletz, Cloud P; Miret, Juan J; Lizotte, Patrick H; Gokhale, Prafulla C; Jänne, Pasi A; Barbie, David A.
  • Yoshida R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Saigi M; Respiratory Center, Asahikawa Medical University, Hokkaido, Japan.
  • Tani T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Springer BF; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
  • Shibata H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Kitajima S; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Mahadevan NR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Campisi M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Kim W; Department of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research Tokyo, Japan.
  • Kobayashi Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Thai TC; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Haratani K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Yamamoto Y; Jong Wook Kim Ph.D., University of California San Diego, School of Medicine, Moores Cancer Center.
  • Sundararaman SK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Knelson EH; Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan.
  • Vajdi A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Canadas I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Uppaluri R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Paweletz CP; Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Miret JJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Lizotte PH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Gokhale PC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Jänne PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Barbie DA; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Cancer Res ; 82(21): 4079-4092, 2022 11 02.
Article en En | MEDLINE | ID: mdl-36066413
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2022 Tipo del documento: Article